SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 8, 2021
REGEN BIOPHARMA, INC.
(Exact name of small business issuer as specified in its charter)
|(State or other jurisdiction of incorporation or organization)||(I.R.S. Employer Identification No.)|
Commission File No. 333-191725
711 S. Carson Street, Suite 4, Carson City, Nevada, 89791
(Address of Principal Executive Offices)
(619) 702 1404
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
Regen Biopharma, Inc. (the “Company”) is in the process of preparing financial statements in order that Company may have such statements audited (in the case of Annual Financial Statements) and reviewed (in the case of Quarterly Financial Statements).
Upon completion of the aforementioned audits and reviews and preparation of the required reports, the Company intends file the following delinquent periodic reports with United States Securities and Exchange Commission:
|•||Form 10-K for the Fiscal Year ended September 30, 2019|
|•||Form 10-Q for the Quarter ended December 31, 2019|
|•||Form 10-Q for the Quarter ended March 31, 2020|
|•||Form 10-Q for the Quarter ended June 30, 2020|
|•||Form 10-K for the Fiscal Year ended September 30, 2020|
|•||Form 10-Q for the Quarter ended December 31, 2020|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|REGEN BIOPHARMA, INC.|
|Dated: April 8, 2021||By: /s/ David Koos|
|Chief Executive Officer|